Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL570930 | 1.00 | SLC2A1 (0.37) | SLC2A1SLC6A2SLC6A4SLC6A3NOS1 | |
| Hydrochloric Acid SCHEMBL19378047 | 0.98 | SLC2A1 (0.36) | SLC2A1SLC6A2SLC6A4SLC6A3NOS1 | |
| SCHEMBL23505839 | 0.84 | SLC2A1 (0.37) | SLC2A1NOS1NOS2MAP3K14ADRA2A | |
| SCHEMBL25659975 | 0.79 | HTR2A (0.38) | SLC2A1NOS1NOS2MAP3K14ADRA2A | |
| Hydrochloric Acid SCHEMBL31715373 | 0.78 | NPC1 (0.33) | — | |
| SCHEMBL3847929 | 0.75 | ADRA2A (0.50) | SLC6A2SLC6A4SLC6A3ADRA2AADRA2B | |
| SCHEMBL31316665 | 0.75 | ADRA2A (0.50) | SLC6A2SLC6A4SLC6A3ADRA2AADRA2B | |
| SCHEMBL27509754 | 0.75 | SLC2A1 (0.35) | SLC2A1MAP3K14ADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL31316673 | 0.74 | ADRA2A (0.49) | SLC6A2SLC6A4SLC6A3ADRA2AADRA2B | |
| SCHEMBL6340390 | 0.73 | CNR1 (0.34) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| US-10889573-B2 | Anthelmintic quinoline-3-carboxamide derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
| EP-2601193-B1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY AGAINST CLOSTRIDIUM | ELANCO ANIMAL HEALTH IRELAND (IE) | 2015-03-11 | — | — | EP | disclosed |
| US-8618100-B2 | Compounds with antibacterial activity against Clostridium | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2601193-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY AGAINST CLOSTRIDIUM | Elanco Animal Health Ireland Limited (IE) | 2013-06-12 | — | — | EP | disclosed |
| US-20130109694-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY AGAINST CLOSTRIDIUM | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-05-02 | — | — | US | disclosed |
| WO-2012017030-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY AGAINST CLOSTRIDIUM | ELANCO ANIMAL HEALTH IRELAND LIMITED (IE) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109694-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY AGAINST CLOSTRIDIUM | VIP, PRF1, C5 | SLC2A1 4370/4885SLC6A2 4363/4885SLC6A4 3374/4885 |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | AARS1, MTR, GARS1 | SLC2A1 2736/4885SLC6A2 3000/4885SLC6A4 2505/4885 |
| US-10889573-B2 | Anthelmintic quinoline-3-carboxamide derivatives | HRH4, HRH2, H1-5 | SLC2A1 4840/4885SLC6A2 4297/4885SLC6A4 3899/4885 |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | AARS1, MTR, GARS1 | SLC2A1 2736/4885SLC6A2 3000/4885SLC6A4 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.